<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39339997</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2076-393X</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Aug</Month><Day>26</Day></PubDate></JournalIssue><Title>Vaccines</Title><ISOAbbreviation>Vaccines (Basel)</ISOAbbreviation></Journal><ArticleTitle>Design, Immunogenicity and Preclinical Efficacy of the ChAdOx1.COVconsv12 Pan-Sarbecovirus T-Cell Vaccine.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">965</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/vaccines12090965</ELocationID><Abstract><AbstractText>During the COVID-19 pandemic, antibody-based vaccines targeting the SARS-CoV-2 spike glycoprotein were the focus for development because neutralizing antibodies were associated with protection against the SARS-CoV-2 infection pre-clinically and in humans. While deploying these spike-based vaccines saved millions of lives worldwide, it has become clear that the immunological mechanisms of protection against severe disease are multifaceted and involve non-neutralizing antibody components. Here, we describe a novel pan-sarbecovirus T-cell vaccine, ChAdOx1.COVconsv12, designed to complement and broaden the protection of spike vaccines. The vaccine immunogen COVconsv12 employs the two regions in the viral proteome most conserved among sarbecoviruses, which are delivered by replication-deficient vector ChAdOx1. It directs T cells towards epitopes shared among sarbecoviruses including evolving SARS-CoV-2 variants. Here, we show that ChAdOx1.COVconsv12 induced broad T-cell responses in the BALB/c and C57BL/6 mice. In the Syrian hamster challenge model, ChAdOx1.COVconsv12 alone did not protect against the SARS-CoV-2 infection, but when co-administered with 1/50th of the ChAdOx1 nCoV-19 spike vaccine protective dose, faster recovery and lower oral swab viral load were observed. Induction of CD8<sup>+</sup> T cells may decrease COVID-19 severity and extend the T-cell response coverage of variants to match the known (and as yet unknown) members of the β-coronavirus family.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wee</LastName><ForeName>Edmund G-T</ForeName><Initials>EG</Initials><AffiliationInfo><Affiliation>The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford OX3 7DQ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kempster</LastName><ForeName>Sarah</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-4309-1489</Identifier><AffiliationInfo><Affiliation>Science and Research-Diagnostics, Medicines and Healthcare products Regulatory Agency, Potters Bar EN6 3QG, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferguson</LastName><ForeName>Deborah</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Science and Research-Diagnostics, Medicines and Healthcare products Regulatory Agency, Potters Bar EN6 3QG, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hall</LastName><ForeName>Joanna</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Science and Research-Diagnostics, Medicines and Healthcare products Regulatory Agency, Potters Bar EN6 3QG, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ham</LastName><ForeName>Claire</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0003-0734-2129</Identifier><AffiliationInfo><Affiliation>Science and Research-Diagnostics, Medicines and Healthcare products Regulatory Agency, Potters Bar EN6 3QG, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>Susan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Pandemic Sciences Institute, Nuffield Department of Medicine, University of Oxford, Oxford OX3 7DQ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Crook</LastName><ForeName>Alison</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-9724-8309</Identifier><AffiliationInfo><Affiliation>The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford OX3 7DQ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gilbert</LastName><ForeName>Sarah C</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>Pandemic Sciences Institute, Nuffield Department of Medicine, University of Oxford, Oxford OX3 7DQ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Korber</LastName><ForeName>Bette</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>New Mexico Consortium, Los Alamos, NM 87544, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Almond</LastName><ForeName>Neil</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0001-6105-0616</Identifier><AffiliationInfo><Affiliation>Science and Research-Diagnostics, Medicines and Healthcare products Regulatory Agency, Potters Bar EN6 3QG, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hanke</LastName><ForeName>Tomáš</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford OX3 7DQ, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto 860-0811, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>08</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Vaccines (Basel)</MedlineTA><NlmUniqueID>101629355</NlmUniqueID><ISSNLinking>2076-393X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19 T cells</Keyword><Keyword MajorTopicYN="N">COVID-19 vaccine</Keyword><Keyword MajorTopicYN="N">ChAdOx1</Keyword><Keyword MajorTopicYN="N">Syrian hamster</Keyword><Keyword MajorTopicYN="N">T cell vaccine</Keyword><Keyword MajorTopicYN="N">T cells</Keyword><Keyword MajorTopicYN="N">challenge</Keyword><Keyword MajorTopicYN="N">conserved region</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>1</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>8</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39339997</ArticleId><ArticleId IdType="pmc">PMC11436245</ArticleId><ArticleId IdType="doi">10.3390/vaccines12090965</ArticleId><ArticleId IdType="pii">vaccines12090965</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Fischer R.J., van Doremalen N., Adney D.R., Yinda C.K., Port J.R., Holbrook M.G., Schulz J.E., Williamson B.N., Thomas T., Barbian K., et al. ChAdOx1 nCoV-19 (AZD1222) protects Syrian hamsters against SARS-CoV-2 B.1.351 and B.1.1.7. Nat. Commun. 2021;12:5868. doi: 10.1038/s41467-021-26178-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-26178-y</ArticleId><ArticleId IdType="pmc">PMC8497486</ArticleId><ArticleId IdType="pubmed">34620866</ArticleId></ArticleIdList></Reference><Reference><Citation>McMahan K., Yu J., Mercado N.B., Loos C., Tostanoski L.H., Chandrashekar A., Liu J., Peter L., Atyeo C., Zhu A., et al. Correlates of protection against SARS-CoV-2 in rhesus macaques. Nature. 2021;590:630–634. doi: 10.1038/s41586-020-03041-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-03041-6</ArticleId><ArticleId IdType="pmc">PMC7906955</ArticleId><ArticleId IdType="pubmed">33276369</ArticleId></ArticleIdList></Reference><Reference><Citation>Tostanoski L.H., Wegmann F., Martinot A.J., Loos C., McMahan K., Mercado N.B., Yu J., Chan C.N., Bondoc S., Starke C.E., et al. Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters. Nat. Med. 2020;26:1694–1700. doi: 10.1038/s41591-020-1070-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-1070-6</ArticleId><ArticleId IdType="pmc">PMC7671939</ArticleId><ArticleId IdType="pubmed">32884153</ArticleId></ArticleIdList></Reference><Reference><Citation>Baden L.R., El Sahly H.M., Essink B., Kotloff K., Frey S., Novak R., Diemert D., Spector S.A., Rouphael N., Creech C.B., et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N. Engl. J. Med. 2021;384:403–416. doi: 10.1056/NEJMoa2035389.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2035389</ArticleId><ArticleId IdType="pmc">PMC7787219</ArticleId><ArticleId IdType="pubmed">33378609</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng S., Phillips D.J., White T., Sayal H., Aley P.K., Bibi S., Dold C., Fuskova M., Gilbert S.C., Hirsch I., et al. Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. Nat. Med. 2021;27:2032–2040. doi: 10.1038/s41591-021-01540-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01540-1</ArticleId><ArticleId IdType="pmc">PMC8604724</ArticleId><ArticleId IdType="pubmed">34588689</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilbert P.B., Montefiori D.C., McDermott A.B., Fong Y., Benkeser D., Deng W., Zhou H., Houchens C.R., Martins K., Jayashankar L., et al. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science. 2022;375:43–50. doi: 10.1126/science.abm3425.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abm3425</ArticleId><ArticleId IdType="pmc">PMC9017870</ArticleId><ArticleId IdType="pubmed">34812653</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh K.A., Jordan K., Clyne B., Rohde D., Drummond L., Byrne P., Ahern S., Carty P.G., O’Brien K.K., O’Murchu E., et al. SARS-CoV-2 detection, viral load and infectivity over the course of an infection. J. Infect. 2020;81:357–371. doi: 10.1016/j.jinf.2020.06.067.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2020.06.067</ArticleId><ArticleId IdType="pmc">PMC7323671</ArticleId><ArticleId IdType="pubmed">32615199</ArticleId></ArticleIdList></Reference><Reference><Citation>Tregoning J.S., Flight K.E., Higham S.L., Wang Z., Pierce B.F. Progress of the COVID-19 vaccine effort: Viruses, vaccines and variants versus efficacy, effectiveness and escape. Nat. Rev. Immunol. 2021;21:626–636. doi: 10.1038/s41577-021-00592-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-021-00592-1</ArticleId><ArticleId IdType="pmc">PMC8351583</ArticleId><ArticleId IdType="pubmed">34373623</ArticleId></ArticleIdList></Reference><Reference><Citation>Willett B.J., Grove J., MacLean O.A., Wilkie C., De Lorenzo G., Furnon W., Cantoni D., Scott S., Logan N., Ashraf S., et al. SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway. Nat. Microbiol. 2022;7:1161–1179. doi: 10.1038/s41564-022-01143-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41564-022-01143-7</ArticleId><ArticleId IdType="pmc">PMC9352574</ArticleId><ArticleId IdType="pubmed">35798890</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahrokhian S.H., Tostanoski L.H., Vidal S.J., Barouch D.H. COVID-19 vaccines: Immune correlates and clinical outcomes. Hum. Vaccin. Immunother. 2024;20:2324549. doi: 10.1080/21645515.2024.2324549.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2024.2324549</ArticleId><ArticleId IdType="pmc">PMC10962618</ArticleId><ArticleId IdType="pubmed">38517241</ArticleId></ArticleIdList></Reference><Reference><Citation>Dagotto G., Ventura J.D., Martinez D.R., Anioke T., Chung B.S., Siamatu M., Barrett J., Miller J., Schafer A., Yu J., et al. Immunogenicity and protective efficacy of a rhesus adenoviral vaccine targeting conserved COVID-19 replication transcription complex. NPJ Vaccines. 2022;7:125. doi: 10.1038/s41541-022-00553-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41541-022-00553-2</ArticleId><ArticleId IdType="pmc">PMC9610341</ArticleId><ArticleId IdType="pubmed">36302778</ArticleId></ArticleIdList></Reference><Reference><Citation>Tarke A., Coelho C.H., Zhang Z., Dan J.M., Yu E.D., Methot N., Bloom N.I., Goodwin B., Phillips E., Mallal S., et al. SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to Omicron. Cell. 2022;185:847–859.E11. doi: 10.1016/j.cell.2022.01.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.01.015</ArticleId><ArticleId IdType="pmc">PMC8784649</ArticleId><ArticleId IdType="pubmed">35139340</ArticleId></ArticleIdList></Reference><Reference><Citation>Kingstad-Bakke B., Lee W., Chandrasekar S.S., Gasper D.J., Salas-Quinchucua C., Cleven T., Sullivan J.A., Talaat A., Osorio J.E., Suresh M. Vaccine-induced systemic and mucosal T cell immunity to SARS-CoV-2 viral variants. Proc. Natl. Acad. Sci. USA. 2022;119:e2118312119. doi: 10.1073/pnas.2118312119.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2118312119</ArticleId><ArticleId IdType="pmc">PMC9171754</ArticleId><ArticleId IdType="pubmed">35561224</ArticleId></ArticleIdList></Reference><Reference><Citation>Koutsakos M., Reynaldi A., Lee W.S., Nguyen J., Amarasena T., Taiaroa G., Kinsella P., Liew K.C., Tran T., Kent H.E., et al. SARS-CoV-2 breakthrough infection induces rapid memory and de novo T cell responses. Immunity. 2023;56:879–892.e4. doi: 10.1016/j.immuni.2023.02.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2023.02.017</ArticleId><ArticleId IdType="pmc">PMC9970913</ArticleId><ArticleId IdType="pubmed">36958334</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo L., Zhang Q., Gu X., Ren L., Huang T., Li Y., Zhang H., Liu Y., Zhong J., Wang X., et al. Durability and cross-reactive immune memory to SARS-CoV-2 in individuals 2 years after recovery from COVID-19: A longitudinal cohort study. Lancet Microbe. 2024;5:e24–e33. doi: 10.1016/S2666-5247(23)00255-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2666-5247(23)00255-0</ArticleId><ArticleId IdType="pmc">PMC10789611</ArticleId><ArticleId IdType="pubmed">38048805</ArticleId></ArticleIdList></Reference><Reference><Citation>Keeton R., Tincho M.B., Suzuki A., Benede N., Ngomti A., Baguma R., Chauke M.V., Mennen M., Skelem S., Adriaanse M., et al. Impact of SARS-CoV-2 exposure history on the T cell and IgG response. Cell Rep. Med. 2023;4:100898. doi: 10.1016/j.xcrm.2022.100898.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrm.2022.100898</ArticleId><ArticleId IdType="pmc">PMC9771741</ArticleId><ArticleId IdType="pubmed">36584684</ArticleId></ArticleIdList></Reference><Reference><Citation>Phan J.M., Layton E.D., Yu K.K.Q., Aguilar M.S., Golez I., Franko N.M., Logue J.K., Rodda L.B., Howard C.A., Pepper M., et al. Cytotoxic T Cells Targeting Spike Glycoprotein Are Associated with Hybrid Immunity to SARS-CoV-2. J. Immunol. 2023;210:1236–1246. doi: 10.4049/jimmunol.2200815.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.2200815</ArticleId><ArticleId IdType="pmc">PMC10121904</ArticleId><ArticleId IdType="pubmed">36961450</ArticleId></ArticleIdList></Reference><Reference><Citation>Augusto D.G., Murdolo L.D., Chatzileontiadou D.S.M., Sabatino J.J., Jr., Yusufali T., Peyser N.D., Butcher X., Kizer K., Guthrie K., Murray V.W., et al. A common allele of HLA is associated with asymptomatic SARS-CoV-2 infection. Nature. 2023;620:128–136. doi: 10.1038/s41586-023-06331-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-023-06331-x</ArticleId><ArticleId IdType="pmc">PMC10396966</ArticleId><ArticleId IdType="pubmed">37468623</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu C., Chen X., Cai Y., Xia J., Zhou X., Xu S., Huang H., Zhang L., Zhou X., Du C., et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients with Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med. 2020;180:934–943. doi: 10.1001/jamainternmed.2020.0994.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2020.0994</ArticleId><ArticleId IdType="pmc">PMC7070509</ArticleId><ArticleId IdType="pubmed">32167524</ArticleId></ArticleIdList></Reference><Reference><Citation>Briceno O., Lissina A., Wanke K., Afonso G., von Braun A., Ragon K., Miquel T., Gostick E., Papagno L., Stiasny K., et al. Reduced naive CD8(+) T-cell priming efficacy in elderly adults. Aging Cell. 2016;15:14–21. doi: 10.1111/acel.12384.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/acel.12384</ArticleId><ArticleId IdType="pmc">PMC4717282</ArticleId><ArticleId IdType="pubmed">26472076</ArticleId></ArticleIdList></Reference><Reference><Citation>Qi Q., Liu Y., Cheng Y., Glanville J., Zhang D., Lee J.Y., Olshen R.A., Weyand C.M., Boyd S.D., Goronzy J.J. Diversity and clonal selection in the human T-cell repertoire. Proc. Natl. Acad. Sci. USA. 2014;111:13139–13144. doi: 10.1073/pnas.1409155111.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1409155111</ArticleId><ArticleId IdType="pmc">PMC4246948</ArticleId><ArticleId IdType="pubmed">25157137</ArticleId></ArticleIdList></Reference><Reference><Citation>Letourneau S., Im E.J., Mashishi T., Brereton C., Bridgeman A., Yang H., Dorrell L., Dong T., Korber B., McMichael A.J., et al. Design and pre-clinical evaluation of a universal HIV-1 vaccine. PLoS ONE. 2007;2:e984. doi: 10.1371/journal.pone.0000984.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0000984</ArticleId><ArticleId IdType="pmc">PMC1991584</ArticleId><ArticleId IdType="pubmed">17912361</ArticleId></ArticleIdList></Reference><Reference><Citation>Ondondo B., Murakoshi H., Clutton G., Abdul-Jawad S., Wee E.G., Gatanaga H., Oka S., McMichael A.J., Takiguchi M., Korber B., et al. Novel Conserved-region T-cell Mosaic Vaccine With High Global HIV-1 Coverage Is Recognized by Protective Responses in Untreated Infection. Mol. Ther. 2016;24:832–842. doi: 10.1038/mt.2016.3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mt.2016.3</ArticleId><ArticleId IdType="pmc">PMC4886941</ArticleId><ArticleId IdType="pubmed">26743582</ArticleId></ArticleIdList></Reference><Reference><Citation>Rolland M., Nickle D.C., Mullins J.I. HIV-1 group M conserved elements vaccine. PLoS Pathog. 2007;3:e157. doi: 10.1371/journal.ppat.0030157.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.0030157</ArticleId><ArticleId IdType="pmc">PMC2098811</ArticleId><ArticleId IdType="pubmed">18052528</ArticleId></ArticleIdList></Reference><Reference><Citation>Grifoni A., Sidney J., Vita R., Peters B., Crotty S., Weiskopf D., Sette A. SARS-CoV-2 human T cell epitopes: Adaptive immune response against COVID-19. Cell Host Microbe. 2022;30:1788. doi: 10.1016/j.chom.2022.10.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2022.10.017</ArticleId><ArticleId IdType="pmc">PMC9749374</ArticleId><ArticleId IdType="pubmed">36521443</ArticleId></ArticleIdList></Reference><Reference><Citation>Nesamari R., Omondi M.A., Baguma R., Hoft M.A., Ngomti A., Nkayi A.A., Besethi A.S., Magugu S.F.J., Mosala P., Walters A., et al. Post-pandemic memory T cell response to SARS-CoV-2 is durable, broadly targeted, and cross-reactive to the hypermutated BA.2.86 variant. Cell Host Microbe. 2024;32:162–169.e3. doi: 10.1016/j.chom.2023.12.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2023.12.003</ArticleId><ArticleId IdType="pmc">PMC10901529</ArticleId><ArticleId IdType="pubmed">38211583</ArticleId></ArticleIdList></Reference><Reference><Citation>Theiler J., Korber B. Graph-based optimization of epitope coverage for vaccine antigen design. Stat. Med. 2018;37:181–194. doi: 10.1002/sim.7203.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.7203</ArticleId><ArticleId IdType="pmc">PMC5763320</ArticleId><ArticleId IdType="pubmed">28132437</ArticleId></ArticleIdList></Reference><Reference><Citation>Carpenter R.E., Tamrakar V.K., Almas S., Brown E., Sharma R. COVIDSeq as Laboratory Developed Test (LDT) for Diagnosis of SARS-CoV-2 Variants of Concern (VOC) Arch. Clin. Biomed. Res. 2022;6:954–970. doi: 10.26502/acbr.50170309.</Citation><ArticleIdList><ArticleId IdType="doi">10.26502/acbr.50170309</ArticleId><ArticleId IdType="pmc">PMC9802674</ArticleId><ArticleId IdType="pubmed">36588916</ArticleId></ArticleIdList></Reference><Reference><Citation>Khare S., Gurry C., Freitas L., Schultz M.B., Bach G., Diallo A., Akite N., Ho J., Lee R.T., Yeo W., et al. GISAID’s Role in Pandemic Response. China CDC Wkly. 2021;3:1049–1051. doi: 10.46234/ccdcw2021.255.</Citation><ArticleIdList><ArticleId IdType="doi">10.46234/ccdcw2021.255</ArticleId><ArticleId IdType="pmc">PMC8668406</ArticleId><ArticleId IdType="pubmed">34934514</ArticleId></ArticleIdList></Reference><Reference><Citation>Katoh K., Rozewicki J., Yamada K.D. MAFFT online service: Multiple sequence alignment, interactive sequence choice and visualization. Brief. Bioinform. 2019;20:1160–1166. doi: 10.1093/bib/bbx108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bib/bbx108</ArticleId><ArticleId IdType="pmc">PMC6781576</ArticleId><ArticleId IdType="pubmed">28968734</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu B., Zhao P., Xu P., Han Y., Wang Y., Chen L., Wu Z., Yang J. A comprehensive dataset of animal-associated sarbecoviruses. Sci. Data. 2023;10:681. doi: 10.1038/s41597-023-02558-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41597-023-02558-5</ArticleId><ArticleId IdType="pmc">PMC10560225</ArticleId><ArticleId IdType="pubmed">37805633</ArticleId></ArticleIdList></Reference><Reference><Citation>Trifinopoulos J., Nguyen L.T., von Haeseler A., Minh B.Q. W-IQ-TREE: A fast online phylogenetic tool for maximum likelihood analysis. Nucleic Acids Res. 2016;44:W232–W235. doi: 10.1093/nar/gkw256.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkw256</ArticleId><ArticleId IdType="pmc">PMC4987875</ArticleId><ArticleId IdType="pubmed">27084950</ArticleId></ArticleIdList></Reference><Reference><Citation>Hannoun Z., Wee E.G., Crook A., Colloca S., Di Marco S., Hanke T. Adenovirus DNA Polymerase Loses Fidelity on a Stretch of Eleven Homocytidines during Pre-GMP Vaccine Preparation. Vaccines. 2022;10:960. doi: 10.3390/vaccines10060960.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10060960</ArticleId><ArticleId IdType="pmc">PMC9227658</ArticleId><ArticleId IdType="pubmed">35746566</ArticleId></ArticleIdList></Reference><Reference><Citation>Folegatti P.M., Ewer K.J., Aley P.K., Angus B., Becker S., Belij-Rammerstorfer S., Bellamy D., Bibi S., Bittaye M., Clutterbuck E.A., et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: A preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020;396:467–478. doi: 10.1016/S0140-6736(20)31604-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)31604-4</ArticleId><ArticleId IdType="pmc">PMC7445431</ArticleId><ArticleId IdType="pubmed">32702298</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanke T., Szawlowski P., Randall R.E. Construction of solid matrix-antibody-antigen complexes containing simian immunodeficiency virus p27 using tag-specific monoclonal antibody and tag-linked antigen. J. Gen. Virol. 1992;73:653–660. doi: 10.1099/0022-1317-73-3-653.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/0022-1317-73-3-653</ArticleId><ArticleId IdType="pubmed">1372038</ArticleId></ArticleIdList></Reference><Reference><Citation>Beavis A.C., Wee E.G., Akis Yildirim B.M., Borthwick N., He B., Hanke T. Combined intranasal and intramuscular parainfluenza 5-, simian adenovirus ChAdOx1- and poxvirus MVA-vectored vaccines induce synergistically HIV-1-specific T cells in the mucosa. Front. Immunol. 2023;14:1186478. doi: 10.3389/fimmu.2023.1186478.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1186478</ArticleId><ArticleId IdType="pmc">PMC10390215</ArticleId><ArticleId IdType="pubmed">37529048</ArticleId></ArticleIdList></Reference><Reference><Citation>Wee E.G., Moyo N., Hannoun Z., Giorgi E., Korber B., Hanke T. Effect of epitope variant co-delivery on the depth of CD8 T-cell responses induced by HIV-1 conserved mosaic vaccines. Mol. Ther. Methods Clin. Dev. 2021;21:741–753. doi: 10.1016/j.omtm.2021.04.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.omtm.2021.04.018</ArticleId><ArticleId IdType="pmc">PMC8187930</ArticleId><ArticleId IdType="pubmed">34169114</ArticleId></ArticleIdList></Reference><Reference><Citation>Vierbaum L., Wojtalewicz N., Grunert H.P., Lindig V., Duehring U., Drosten C., Corman V., Niemeyer D., Ciesek S., Rabenau H.F., et al. RNA reference materials with defined viral RNA loads of SARS-CoV-2-A useful tool towards a better PCR assay harmonization. PLoS ONE. 2022;17:e0262656. doi: 10.1371/journal.pone.0262656.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0262656</ArticleId><ArticleId IdType="pmc">PMC8775330</ArticleId><ArticleId IdType="pubmed">35051208</ArticleId></ArticleIdList></Reference><Reference><Citation>Caly L., Druce J., Roberts J., Bond K., Tran T., Kostecki R., Yoga Y., Naughton W., Taiaroa G., Seemann T., et al. Isolation and rapid sharing of the 2019 novel coronavirus (SARS-CoV-2) from the first patient diagnosed with COVID-19 in Australia. Med. J. Aust. 2020;212:459–462. doi: 10.5694/mja2.50569.</Citation><ArticleIdList><ArticleId IdType="doi">10.5694/mja2.50569</ArticleId><ArticleId IdType="pmc">PMC7228321</ArticleId><ArticleId IdType="pubmed">32237278</ArticleId></ArticleIdList></Reference><Reference><Citation>Corman V.M., Landt O., Kaiser M., Molenkamp R., Meijer A., Chu D.K., Bleicker T., Brunink S., Schneider J., Schmidt M.L., et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Eurosurveillance. 2020;25:2000045. doi: 10.2807/1560-7917.ES.2020.25.3.2000045.</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2020.25.3.2000045</ArticleId><ArticleId IdType="pmc">PMC6988269</ArticleId><ArticleId IdType="pubmed">31992387</ArticleId></ArticleIdList></Reference><Reference><Citation>Sullivan E., Sung P.Y., Wu W., Berry N., Kempster S., Ferguson D., Almond N., Jones I.M., Roy P. SARS-CoV-2 Virus-like Particles Produced by a Single Recombinant Baculovirus Generate Anti-S Antibody and Protect against Variant Challenge. Viruses. 2022;14:914. doi: 10.3390/v14050914.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v14050914</ArticleId><ArticleId IdType="pmc">PMC9143203</ArticleId><ArticleId IdType="pubmed">35632656</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao Y., Yan L., Huang Y., Liu F., Zhao Y., Cao L., Wang T., Sun Q., Ming Z., Zhang L., et al. Structure of the RNA-dependent RNA polymerase from COVID-19 virus. Science. 2020;368:779–782. doi: 10.1126/science.abb7498.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abb7498</ArticleId><ArticleId IdType="pmc">PMC7164392</ArticleId><ArticleId IdType="pubmed">32277040</ArticleId></ArticleIdList></Reference><Reference><Citation>Munoz-Fontela C., Dowling W.E., Funnell S.G.P., Gsell P.S., Riveros-Balta A.X., Albrecht R.A., Andersen H., Baric R.S., Carroll M.W., Cavaleri M., et al. Animal models for COVID-19. Nature. 2020;586:509–515. doi: 10.1038/s41586-020-2787-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2787-6</ArticleId><ArticleId IdType="pmc">PMC8136862</ArticleId><ArticleId IdType="pubmed">32967005</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer M., Wang Y., Edwards D., Smith G.R., Rubenstein A.B., Ramanathan P., Mire C.E., Pietzsch C., Chen X., Ge Y., et al. Attenuated activation of pulmonary immune cells in mRNA-1273-vaccinated hamsters after SARS-CoV-2 infection. J. Clin. Investig. 2021;131:e148036. doi: 10.1172/JCI148036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI148036</ArticleId><ArticleId IdType="pmc">PMC8516449</ArticleId><ArticleId IdType="pubmed">34449440</ArticleId></ArticleIdList></Reference><Reference><Citation>Benjamini Y., Hochberg Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J. R. Stat. Soc. Ser. B. 1995;57:289–300. doi: 10.1111/j.2517-6161.1995.tb02031.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.2517-6161.1995.tb02031.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Theiler J., Yoon H., Yusim K., Picker L.J., Fruh K., Korber B. Epigraph: A Vaccine Design Tool Applied to an HIV Therapeutic Vaccine and a Pan-Filovirus Vaccine. Sci. Rep. 2016;6:33987. doi: 10.1038/srep33987.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep33987</ArticleId><ArticleId IdType="pmc">PMC5050445</ArticleId><ArticleId IdType="pubmed">27703185</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahim M.N., Wee E.G., He S., Audet J., Tierney K., Moyo N., Hannoun Z., Crook A., Baines A., Korber B., et al. Complete protection of the BALB/c and C57BL/6J mice against Ebola and Marburg virus lethal challenges by pan-filovirus T-cell epigraph vaccine. PLoS Pathog. 2019;15:e1007564. doi: 10.1371/journal.ppat.1007564.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1007564</ArticleId><ArticleId IdType="pmc">PMC6394903</ArticleId><ArticleId IdType="pubmed">30817809</ArticleId></ArticleIdList></Reference><Reference><Citation>Bullard B.L., DeBeauchamp J., Pekarek M.J., Petro-Turnquist E., Vogel P., Webby R.J., Weaver E.A. An epitope-optimized human H3N2 influenza vaccine induces broadly protective immunity in mice and ferrets. NPJ Vaccines. 2022;7:65. doi: 10.1038/s41541-022-00492-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41541-022-00492-y</ArticleId><ArticleId IdType="pmc">PMC9226166</ArticleId><ArticleId IdType="pubmed">35739199</ArticleId></ArticleIdList></Reference><Reference><Citation>Petro-Turnquist E., Corder Kampfe B., Gadeken A., Pekarek M.J., Weaver E.A. Multivalent Epigraph Hemagglutinin Vaccine Protects against Influenza B Virus in Mice. Pathogens. 2024;13:97. doi: 10.3390/pathogens13020097.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pathogens13020097</ArticleId><ArticleId IdType="pmc">PMC10892733</ArticleId><ArticleId IdType="pubmed">38392835</ArticleId></ArticleIdList></Reference><Reference><Citation>Petro-Turnquist E., Pekarek M., Jeanjaquet N., Wooledge C., Steffen D., Vu H., Weaver E.A. Adenoviral-vectored epigraph vaccine elicits robust, durable, and protective immunity against H3 influenza A virus in swine. Front. Immunol. 2023;14:1143451. doi: 10.3389/fimmu.2023.1143451.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1143451</ArticleId><ArticleId IdType="pmc">PMC10225514</ArticleId><ArticleId IdType="pubmed">37256131</ArticleId></ArticleIdList></Reference><Reference><Citation>Borthwick N., Fernandez N., Hayes P.J., Wee E.G.-T., Akis Yildirim B.M., Baines A., Baker M., Byard N., Conway O., Glaze M., et al. Safety and immunogenicity of the ChAdOx1-MVA-vectored conserved mosaic HIVconsvX candidate T-cell vaccines in HIV-CORE 005.2: An open-label, dose-escalation, first-in-man phase 1 trial in adults living without HIV-1 in the UK. Lancet Microbe. 2024 in press .</Citation></Reference><Reference><Citation>Chanda C., Kibengo F., Mutua M., Muturi-Kioi V., Ogada F., Akis Yildirim B.M., Amond I.M., Baines A., Basajja V., Borthwick N., et al. Safety and broad immunogenicity of HIVconsvX conserved mosaic candidate T-cell vaccines vectored by ChAdOx1 and MVA in HIV-CORE 006: A double-blind, randomized, placebo-controlled phase 1 trial in healthy adults living without HIV-1 in Eastern and Southern Africa. Lancet. 2024 submitted .</Citation></Reference><Reference><Citation>Alter G., Yu J.Y., Liu J.Y., Chandrashekar A., Borducchi E.N., Tostanoski L.H., McMahan K., Jacob-Dolan C., Martinez D.R., Chang A.Q., et al. Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans. Nature. 2021;596:268–272. doi: 10.1038/s41586-021-03681-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03681-2</ArticleId><ArticleId IdType="pmc">PMC8357629</ArticleId><ArticleId IdType="pubmed">34107529</ArticleId></ArticleIdList></Reference><Reference><Citation>Goel R.R., Painter M.M., Apostolidis S.A., Mathew D., Meng W., Rosenfeld A.M., Lundgreen K.A., Reynaldi A., Khoury D.S., Pattekar A., et al. mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern. Science. 2021;374:abm0829. doi: 10.1126/science.abm0829.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abm0829</ArticleId><ArticleId IdType="pmc">PMC9284784</ArticleId><ArticleId IdType="pubmed">34648302</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J., Chandrashekar A., Sellers D., Barrett J., Jacob-Dolan C., Lifton M., McMahan K., Sciacca M., VanWyk H., Wu C., et al. Vaccines elicit highly conserved cellular immunity to SARS-CoV-2 Omicron. Nature. 2022;603:493–496. doi: 10.1038/s41586-022-04465-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04465-y</ArticleId><ArticleId IdType="pmc">PMC8930761</ArticleId><ArticleId IdType="pubmed">35102312</ArticleId></ArticleIdList></Reference><Reference><Citation>Dan J.M., Mateus J., Kato Y., Hastie K.M., Yu E.D., Faliti C.E., Grifoni A., Ramirez S.I., Haupt S., Frazier A., et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science. 2021;371:eabf4063. doi: 10.1126/science.abf4063.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abf4063</ArticleId><ArticleId IdType="pmc">PMC7919858</ArticleId><ArticleId IdType="pubmed">33408181</ArticleId></ArticleIdList></Reference><Reference><Citation>Robbiani D.F., Gaebler C., Muecksch F., Lorenzi J.C.C., Wang Z., Cho A., Agudelo M., Barnes C.O., Gazumyan A., Finkin S., et al. Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature. 2020;584:437–442. doi: 10.1038/s41586-020-2456-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2456-9</ArticleId><ArticleId IdType="pmc">PMC7442695</ArticleId><ArticleId IdType="pubmed">32555388</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>